Monday, March 27, 2017
Breaking News

25B-NBOMe (2C-B-NBOMe)

2C-B-NBOMe-skeletal.svg25B-NBOMe (2C-B-NBOMe) is currently Schedule I in the United States. This went into effect on November 15, 2013.

Addictive Potential: Unknown

Emergency Room Visits Yearly: Unknown

Mandatory Minimum Sentence: Unknown

Mechanism of Action: 5-HT(2A) receptor partial agonist

Overview:

25B-NBOMe is also known as 2C-B-NBOMe and 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine. It was discovered by Ralf Heim in 2004 at Freie Universität Berlin. Recreational users report various methods of ingestion including insufflation, vaporization, and oral administration on blotter paper (Erowid, 2012).

Side Effects & Adverse Reactions:

25B-NBOMe is a very new substance, and little is known about its side effects, adverse reactions, long term damage, and/or addiction potential. Remember, research chemicals are experimental chemicals that are not approved for human consumption. This is because not enough data exists currently about their effects in humans. Although some people are willing to ingest research chemicals, it is not reasonable to assume that they are in any way safe to use recreationally.

Deaths & Hospitalizations:

25B-NBOMe (2C-B-NBOMe) Hospitalization

Research:

Structural elucidation and identification of a new derivative of phenethylamine using quadrupole time of-flight mass spectrometry

More Info:

25B-NBOMe on Drugs Forum

Leave a Reply